Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$7.6 million on sales of $24.7 million for the 3 months ended Sept. 30, for sales growth of 11% compared with the same period […]
Otolaryngology Ear, Nose & Throat
Frequency completes enrollment in safety trial for hearing loss drug
Frequency Therapeutics said today that it finished enrolling participants in a single-dose safety trial for its FX-322 hearing loss drug candidate. The company’s drug candidate emerged as part of its Progenitor Cell Activation platform – the combination of small molecules are designed to activate progenitor cells and trigger the formation of new hair cells in […]
Anthem adds Intersect ENT’s Sinuva implant to formulary
Anthem this month added Intersect ENT‘s (NSDQ:XENT) Sinuva steroid-releasing implant to its updated formulary as a Tier 3 product, according to a note from Leerink analysts. The product is designated on Anthem’s formulary as “LD” – limited distribution – and is only available to certain pharmacies or wholesalers. Intersect ENT launched the product in the […]
Frequency Therapeutics launches clinical trial for hearing loss drug
Frequency Therapeutics said today that the first patients have been treated in a Phase I/II clinical trial to assess its first-in-class drug candidate for hearing restoration. The 24-patient trial is slated to include people with stable sensorineural hearing loss. Participants will receive an injection of Frequency’s FX-322 or a placebo in one ear, with a follow-up […]
Particle Sciences receives patent for device to deliver medication to the tympanic membrane
[PRESS RELEASE] – The Lubrizol Corporation announces its LifeSciences and Particle Sciences businesses, have received a Notice of Allowance on a device for the delivery of medication to the ear-drum. According to Rob Lee, president, Particle Sciences, “This latest patent is a clear-cut demonstration of our staff going beyond formulation to help our clients deliver […]
Intersect ENT shares tumble on Q2 results
Shares in Intersect ENT (NSDQ:XENT) fell today after the medical device maker missed sales expectations on Wall Street with its second-quarter financial results. The Menlo Park, Calif.-based company posted a net loss of -$4.2 million on sales of $26.3 million for the 3 months ended June 30, for sales growth of 9.7% compared with the same […]
Pavmed lands $10m from oversubscribed rights offering
Pavmed (NSDQ:PAVM) said today that it expects to reel in $10.4 million in gross proceeds from an oversubscribed rights offering that expired this week. The New York-based company received subscriptions exceeding the number of rights available under the offering, Pavmed said, adding that it anticipates the offering will close on June 12. According to the terms […]
Acousia Therapeutics raises $12m
Inner-ear-focused biotech firm Acousia Therapeutics said today it raised $12 million (EU €10 million) in a Series B round of financing, with funds slated to help support their preclinical drug candidates. The Series B round was led by newly invested LBBW Venture Capital and joined by new investors Creathor Ventures and Bregua Corp and existing […]
Pavmed registers for $20m rights offering
Pavmed (NSDQ:PAVM) said today that it filed a preliminary prospectus with the SEC for an offering of the rights to buy a new unit in exchange for each share of outstanding common stock. The medical device company plans to offer the rights to purchase up to 9 million units at $2.25 apiece on May 21, valuing […]
Intersect ENT beats The Street with Q1 sales, earnings
Shares in Intersect ENT (NSDQ:XENT) held steady today after the medical device maker topped expectations on Wall Street with its first-quarter results. The Menlo Park, Calif.-based company posted a net loss of -$6.1 million, or -21¢ per share, on sales of $24.7 million for the 3 months ended March 31, for bottom-line growth of 8.8% on […]